Introduction: Glutathione S-transferase pi 1 metabolizes carcinogens from tobacco smoke in the lung. We tested whether genetically altered glutathione S-transferase pi 1 activity affects lung function and risk for tobacco-related cancer and mortality in the general population.
Introduction
Glutathione S-transferases (GSTs) are a superfamily of enzymes catalyzing the detoxification of reactive electrophilic compounds and thereby protecting cells from bioactive xenobiotics and reactive oxidative substances. 1 Glutathione S-transferase pi 1 (GSTP1) is highly expressed in lung tissue 2, 3 and is considered the predominant GST in the lungs. 4, 5 Two genetic variants in glutathione S-transferase pi 1 gene (GSTP1)-Ile105Val (amino acid isoleucine 105 changed to a valine [rs1695]) and Ala114Val (amino acid alanine 114 changed to a valine [rs1138272])-have been shown to confer altered catalytic activity of GSTP1. [6] [7] [8] [9] Ile105Val is located in the substrate binding site of GSTP1 and associated with higher activity against carcinogenic metabolites of polycyclic aromatic hydrocarbons from air pollutants such as tobacco smoke. 8, 9 One such substrate is the carcinogenic diol epoxide of benzo(a)pyrene from smoke, which has been shown to cause mutations in the tumor protein p53 gene (TP53) at *Corresponding author.
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mutational hot spots that are characteristic for lung cancer. 10 Meta-analyses have found associations between Ile105Val and risk for lung cancer in some ethnic populations 11, 12 but not in others. 13, 14 The less studied variant, Ala114Val, has also been associated with lung cancer and overall cancer in a recent meta-analysis. 15 These meta-analyses have in common that the individual studies are generally small case-control studies from many different centers around the world.
We tested the hypothesis that genetically altered GSTP1 activity associates with risk for lung cancer, tobacco-related cancer, and mortality in the general population. For this purpose we genotyped for Ile105Val and Ala114Val in two large prospective cohort studies of the white general population comprising 66,069 study participants. As a secondary aim we also assessed association with lung function.
Methods
Studies were approved by institutional review boards and Danish ethical committees and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from participants. All participants were of white descent, as determined by the National Danish Civil Registration System.
Participants
We included participants in two similar studies of the white general population, the Copenhagen General Population Study (CGPS) and the Copenhagen City Heart Study (CCHS). Combining these two studies yielded a total population of 66.069, within which 527 cases of lung cancer and 1075 cases of tobacco-related cancer developed and 6356 deaths during follow-up occurred.
CGPS
This study of the white general population was initiated in 2003 with ongoing enrollment. [16] [17] [18] Individuals were selected on the basis of the National Danish Civil Registration System to reflect the adult white population age 20 to 100 years or older. Data were obtained from a questionnaire and a physical examination, and blood samples were drawn for DNA extraction. We included 55,756 consecutive participants from this study in the present analysis; within this group, 207 cases of lung cancer and 409 cases of tobacco-related cancer developed and 2302 deaths occurred during median follow-up times of 2.6 years, 2.6 years, and 4.6 years, respectively.
CCHS
CCHS is another independent study of the white general population initiated in 1976-1978 with follow-up examinations in 1981-1983, 1991-1994, and 2001-2003 . [16] [17] [18] 
End Points
Forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) were determined with a dry wedge spirometer (Vitalograph [Maids Moreton, Buckinghamshire, UK]) in the CCHS and in the first 14,624 participants of the CGPS. For the remaining participants of the CGPS, an EasyOne Spirometer (NDD Medizintechnik, Zürich, Switzerland) was used. Each spirometry was performed in triplicate, and the results were accepted only if variation between the two best performing of these was less than 5%. The best results were used in the analyses. Algorithms for calculation of FEV 1 % predicted and FVC % predicted were made separately in each study by using multiple regressions with age and height as covariates on all individuals for men and women separately. 19 Thus, the FEV 1 % predicted and FVC % predicted values are adjusted for age, sex, and height.
We used the National Danish Cancer Registry, which identifies 98% of all cancers diagnosed in Denmark, 20, 21 to obtain cancer diagnoses for all participants from January 1943 through December 2009. All diagnoses in the registry are assigned on the basis of histological examination by a fully trained pathologist. Cancer diagnoses were classified according to the WHO International Classification of Diseases, Seventh Revision, (ICD-7) (codes 140-205) and International Classification of Diseases, 10th Revision, (ICD-10) (codes C00-D09) and grouped into 25 standard cancer types. 22 Our end points were lung cancer (ICD-7 codes 162-164 and 462.2-462.4 and ICD-10 codes C33-C34 and C38), and tobacco-related cancer, which consists of the following cancers for which smoking has been shown to be a likely causal factor We used the Danish Central Person Registry to obtain the date of death for all participants. All-cause mortality was defined as any death regardless of cause of death. None of the participants were lost to follow-up, and those emigrating were censored at the date of emigration. We further classified all deaths according to the cause of death by using the National Danish Death Register, which is based on the death certificate information reported by the attending physician at the hospital or in general practice when a person dies in Denmark. We used the International Classification of Diseases, Eighth Revision, and ICD-10 diagnoses to classify all deaths as death from lung cancer and tobacco-related cancer.
Genotyping
We genotyped for two common variants in GSTP1, c.313 A>G (Ile105Val, rs1695) and c.341 C>T (Ala114Val, rs1138272), which have been shown to confer or are suspected of conferring increased catalytic activity toward carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. 8, 9 Genotyping was performed with TaqMan-based assays and an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) or an allelespecific polymerase chain reaction system (KASPar [LGC Genomics Ltd., Hoddesdon, Herts, UK]).
Covariates
Baseline characteristics were recorded or derived from data collected at the day of examination on the basis of physical examination and the self-administered questionnaire. Smoking status was self-reported, and participants were divided into ever-smokers (former and current smokers) and never-smokers. Cumulative tobacco consumption was calculated for former and current smokers in pack-years. A pack-year was defined as smoking 20 cigarettes or the equivalent (20 grams of tobacco) per day for a year. Body mass index (BMI) was calculated from measured weight divided by measured height squared (kg/m 2 ).
Statistical Analysis
Statistical analyses were performed using STATA SE version 12.0 (StataCorp LP, College Station, TX). All statistical tests were two sided. Chi-square tests evaluated Hardy-Weinberg equilibrium. To compare characteristics in individuals by genotype, Kruskal-Wallis analysis of variance was used to compare continuous covariates and Pearson's c 2 test to compare categorical covariates. For trend tests, genotypes were coded 0, 1, or 2. For each of the two variants, the most frequent genotype was used as the reference group (coded 0: Ile105, Ala114). Cuzick's test for trend, an extension of the Wilcoxon rank sum test, was used to compare levels of continuous variables as a function of genotypes (FEV 1 % predicted and FVC % predicted). Cumulative incidences of lung cancer and tobacco-related cancer were plotted against age and genotype by using the Fine-Grey approach to account for the possibility of death as a competing event. Follow-up began at the date on which blood was drawn for DNA extraction and ended at the date of the first relevant cancer diagnosis, death, emigration, or latest update of the Danish Cancer Registry, whichever came first. Similar Cox proportional hazard regression models with age as time scale and left truncation (delayed entry) were used to estimate hazard ratios (HRs) for lung cancer and tobacco-related cancer. Similar analyses were performed for all-cause mortality with censoring at the date of death, emigration, or the latest update of the Danish Civil Registration System, whichever came first. Multivariable adjusted Cox regression models included age, sex, BMI and tobacco smoking (number of pack-years). BMI and pack-years of smoking were on a continuous scale. Population prevented fractions were calculated as in Benichou. 24 
Results
Baseline characteristics by GSTP1 genotypes are shown in Table 1 . Risk factors for lung cancer were equally distributed among genotypes and were therefore Fig. 1 ).
Lung Function
Because GSTs are involved in detoxification of inhaled xenobiotics and reactive oxidative substances, we tested for association between GSTP1 genotypes and lung function. In the combined study, Ile105Val genotype was associated with stepwise increases in FEV 1 % predicted and FVC % predicted of up to 0.51% for FEV 1 % predicted and up to 0.48% for FVC % predicted, in 105Val homozygotes versus 105Ile homozygotes (Fig. 1  [left column] ) (p trend ¼ 0.001 and 0.001, respectively). In sensitivity analyses, the results were similar in the CCHS and CGPS separately but became nonsignificant in the CCHS, most likely because of the smaller number of participants ( Supplementary Fig. 2 ). To examine whether the association between Ile105Val and lung function depended on smoking, we stratified the analysis by smoking status. Among smokers, Ile105Val genotype was associated with stepwise increases in FEV 1 % predicted and FVC % predicted of up to 0.76% for FEV 1 % predicted and up to 0.71% for FVC % predicted in 105Val homozygotes versus 105Ile homozygotes (see Fig. 1 [middle column]) (p trend ¼ 0.002 and 0.002, respectively). Among never-smokers, Ile105Val genotype did not associate with FEV 1 % predicted or FVC % predicted (see Fig. 1 [right column] ). In contrast, Ala114Val genotype did not associate with FEV 1 % predicted or FVC % predicted overall or in smokers or never-smokers (see Fig. 1 ).
Risk for Lung Cancer and Tobacco-Related Cancer
GSTP1 is known to detoxify carcinogenic diol epoxides in tobacco smoke. For this reason, we tested for association between GSTP1 genotypes and risk for lung cancer and tobacco-related cancer as a group. Among the 66,069 participants, 527 cases of lung cancer and 1075 cases of tobacco-related cancer developed. There was a stepwise decrease in the cumulative incidence of both lung cancer and tobacco-related cancer as a function of GSTP1 Ile105Val genotype, with 105Val homozygotes having the lowest risk ( Fig. 2 [left column] ) (p trend <0.05 and 0.03, respectively). The Ala114Val variant was not associated with lung cancer or tobacco-related cancer but showed a similar trend, with 105Val homozygotes having the lowest risk (see Fig. 2 
[right column]).
The multifactorially adjusted HR for lung cancer decreased stepwise as a function of GSTP1 Ile105Val genotype to 0.64 (95% confidence interval [CI]: 0.47-0.89) in 105Val homozygotes versus 105Ile homozygotes ( (see Fig. 3 ) (p trend ¼ 0.01). In sensitivity analyses, the observed trends were similar in heavy tobacco smokers, although the results for tobacco-related cancer became statistically significant for Ala114Val and borderline significant for Ile105Val ( Supplementary Figs. 3 and 4) . No significant associations were seen among light tobacco smokers (see Supplementary Figs. 3 and 4) . In sensitivity analyses, the observed trends were similar in the CCHS and CGPS separately for both lung cancer and tobacco-related cancer but became borderline significant in the CGPS ( Supplementary Figs. 5 and 6 ). For the individual tobacco-related cancers, there were similar nonsignificant trends toward a reduction in risk as a function of Ile105Val genotype for oral cancer, larynx cancer, and esophagus cancer (Supplementary Fig. 7 ). The Ala114Val variant was not significantly associated with lung cancer or tobacco-related cancer in CCHS and CGPS combined or individually (see Fig. 3 and Supplementary Figs. 5 and 6 ).
Mortality
There was a stepwise decrease in the cumulative incidence of death as a function of both GSTP1 Ile105Val and Ala114Val genotypes, with the 105Val and 114Val genotypes having the lowest mortality at a given age (Fig. 4) (p trend ¼ 0.01 and 0.04). In agreement, there was a stepwise decrease in multifactorially adjusted HRs for death as a function of genotypes, with HRs for death decreasing to 0.87 (95% CI: 0.80-0.95) for 105Val homozygotes versus 105Ile homozygotes and to 0.82 (95% CI: 0.59-1.13) for 114Val homozygotes versus 114Ala homozygotes (Fig. 5 ) (p trend ¼ 0.001 and 0.01, respectively). Similar results were observed for both variants in the CCHS, whereas results from the CGPS were not significant, most likely because of the shorter follow-up resulting in considerably fewer events (see Supplementary Fig. 6 ). In accordance with the results for lung function, lung cancer, and tobacco-related cancer, the reduced mortality in Ile105Val and Ala114Val carriers was most pronounced among smokers (see Fig. 5 ) (p trend ¼ 0.002 and 0.004, respectively).
There was also a stepwise decrease in the cumulative incidence of deaths from lung cancer and tobaccorelated cancer as a function of GSTP1 Ile105Val genotype, with the 105Val variant having the lowest mortality at a given age (see Supplementary Fig. 7 ) (p trend ¼ 0.01 and 0.03). In agreement, there was a stepwise decrease in multifactorially adjusted HRs for deaths from lung cancer and tobacco-related cancer as a function of genotypes, with HRs for death from lung cancer and tobacco-related cancer decreasing to 0.57 (0.42-0.78) and 0.72 (0.58-0.88) for 105Val homozygotes versus for 105Ile homozygotes, respectively ( Supplementary Fig. 8 ) (p trend ¼ 0.003 and 0.01, respectively). The Ala114Val variant was not associated with deaths from lung cancer and tobacco-related cancer in the general population (see Supplementary Figs. 7 and 8 ).
Population Prevented Fraction
To assess the contribution of GSTP1 genotype to lung cancer, tobacco-related cancer and death in the cohort, we calculated population prevented fractions for the Ile105Val and Ala114Val variants. The population prevented fraction of lung cancer due to Ile105Val homozygosity was 4.1%, suggesting that 4.1% of cases of lung cancer could be avoided if it were possible to expose everyone to Ile105Val homozygosity. 24 The population prevented fractions of tobacco-related cancer and allcause mortality due to Ile105Val homozygosity were 3,0% and 1.5%, respectively. The population prevented fractions of all-cause mortality due to Ile105Val heterozygosity or Ala114Val heterozygosity were 2.3% and 0.9%, respectively.
Discussion
The main findings of this study of 66,069 individuals from the general population are that GSTP1 Ile105Val genotype is associated with improved lung function, with protection against lung cancer and tobacco-related cancer, and with reduced all-cause mortality. For all end points, the findings were most pronounced in smokers, and they suggested a gene dosage effect. The results support the idea that GSTP1 plays a protective role in smoking-induced deterioration of lung function, lung cancer, tobacco-related cancer, and death in humans. This is the first study to simultaneously assess lung function, risk for lung cancer and tobacco-related cancer, and mortality as a function of GSTP1 genotypes in a large prospective study of an ethnically homogeneous white population. Previous studies have reported associations with lung function or lung cancer viewed in isolation, [11] [12] [13] [14] [15] [26] [27] [28] [29] [30] [31] [32] [33] but to the best of our knowledge, none has reported on risk for tobacco-related cancer or mortality. Other studies have shown significant overrepresentation of lung cancer in patients with chronic obstructive pulmonary disease (COPD), and the current findings support the increasingly acknowledged concept of "chronic lung injury" as a common pathway leading to both COPD and lung cancer by elucidating a new genetic mechanism underlying individual susceptibility. [34] [35] [36] [37] How genetically altered GSTP1 activity may preserve lung function in smokers and protect against lung cancer and death is not known. However, GSTP1 is highly expressed in lung tissue, 2, 3 and it is considered the predominant GST in the lungs. 4 ,5 GSTP1 Ile105Val is a functional variant located in the substrate binding site of GSTP1, and it confers a stepwise increased catalytic activity against carcinogenic metabolites of polycyclic aromatic hydrocarbons from tobacco smoke. Mechanistically, it is therefore highly plausible that the 105Val variant is associated with decreased susceptibility to inhaled cigarette smoke in relation to deterioration of lung function and risk for lung cancer and death in humans.
The Ile105Val variant in GSTP1 was associated with increases in FEV 1 % predicted and FVC % predicted, mainly among smokers. The Ile105Val variant increases the metabolism of benzopyrene diol epoxides in tobacco smoke, 8, 9 and benzopyrene diol epoxides have been shown to adversely affect pulmonary function by inducing oxidative stress and inflammation. 1, 25 Previous studies of Ile105Val and lung function have shown conflicting results, which could be due to differences in study design and different populations included in the studies. [26] [27] [28] [29] [30] [31] [32] [33] We studied a cohort of whites, and our data suggest that altered GSTP1 activity due to Ile105Val is associated with improved lung function, especially in smokers.
The Ile105Val variant was also associated with reduced risk for lung cancer and tobacco-related cancer in the white population. In line with this, Ile105Val has been shown to confer higher activity against metabolites of polycyclic aromatic hydrocarbons from tobacco smoke. 8, 9 Of the several thousand chemicals found in cigarette smoke, at least 55 are known to be carcinogenic and 20 have been found convincingly to induce lung tumors, including polycyclic aromatic hydrocarbons. 38 A pooled analysis has previously shown a decreased risk for lung cancer for heavy smokers carrying the Ile105Val variant 14 ; however, previous meta-analyses found no overall association between Ile105Val and lung cancer in white populations. [12] [13] [14] The Ala114Val variant was not significantly associated with lung cancer or tobaccorelated cancer in the present study, which is in contrast to a recent meta-analysis reporting increased lung cancer risk with Ala114Val. 15 Nevertheless, our data and the pooled analysis of heavy smokers by Cote et al.
14 support an association between the Ile105Val variant and reduced risk for lung cancer.
Ile105Val was also associated with reduced mortality, especially among smokers. This is novel and corroborates with the observations of elevated lung function and reduced risk for lung cancer and tobacco-related cancer in the study. Individuals with the Ala114Val variant had also reduced mortality, particularly among smokers. The fact that individuals with the Ala114Val variant had Figure 5 . Risk for all-cause mortality according to glutathione S-transferase pi 1 gene (GSTP1) variants in the general population, overall and by smoking status. Hazard ratios were determined by Cox regression analysis. Multivariate adjusted models included age, sex, pack-years of smoking, and body mass index. p Values were determined by test for trends. Ile105Val, amino acid isoleucine 105 changed to a valine; Ala114Val, amino acid alanine 114 changed to a valine; CI, confidence interval.
reduced mortality but not significantly less risk for lung cancer and tobacco-related cancer could be due to fewer homozygotes with this variant and less statistical power in the analyses with Ala114Val.
All participants in the present study were white, and although this eliminates any blurring due to ethnical heterogeneity of the study population, our results for lung function, tobacco-related cancer, and death may apply to whites only. Sex and age influences lung function and lung cancer risk significantly, and the findings remained after statistical analyses were adjusted for these and other potential confounders. When individuals with the Ala114Val variant were excluded from the analyses, the overall observed trends were similar for lung function and mortality, whereas the results for lung cancer and tobacco-related cancer became borderline significant (p values 0.05-0.07). Data for histologic subtypes were unfortunately not available for this study; however, 82% of Danish lung cancers are NSCLC, and the results in the study may be limited mainly to this type of lung cancer. 39 Although the Ile105Val variant was associated with improved lung function and protection against lung cancer, tobacco-related cancer, and death, the development of lung cancer may require multiple other genetic mutations and many other environmental factors.
In conclusion, we find that genetically altered GSTP1 activity in the general population is associated with improved lung function, with protection against lung cancer and tobacco-related cancer, and with reduced all-cause mortality. Our data support a significant role of GSTP1 in smoking-induced deterioration of lung function, lung cancer, and death in humans. Because population prevented fractions indicate that cases of tobacco-related cancer could be averted by Ile105Val homozygosity, it is possible that pharmaceuticals mimicking GSTP1 Ile105Val activity could have beneficial effects in smokers.
